Education
About Us
Working with TipRanks
Follow Us
Danaher Corp. (DHR)
NYSE:DHR
Earnings Data
Report Date
Apr 28, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.94Last Year’s EPS
1.88Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized durable strengths: robust free cash flow ($5.3B), consecutive EPS and margin resilience, strong product innovation (new product revenue ~+25% YoY), and clear momentum in bioprocessing and diagnostics (Cepheid, Beckman, Leica, Radiometer). Management acknowledged Q4 margin compression (-130 bps) and pockets of weakness in life sciences consumables, academic funding, equipment orders (still below historical levels) and China policy headwinds, and set conservative FY2026 guidance (3%–6% core growth, EPS $8.35–$8.50). On balance, the company presented improving end-market momentum, disciplined cost actions (~$250M) and strong balance sheet flexibility to pursue M&A, while remaining appropriately cautious on near-term variability and execution risks.Company Guidance
Strong full-year financial performance
FY2025 sales of $24.6B; core revenue +2% YoY; adjusted operating profit margin 28.2%; adjusted diluted EPS $7.80, up 4.5% YoY; free cash flow $5.3B and FCF-to-net-income conversion ~145% (34th consecutive year >100%).
Robust fourth-quarter finish
Q4 2025 sales $6.8B with 2.5% core revenue growth; Q4 adjusted diluted EPS $2.23, up 4% YoY; Q4 free cash flow $1.8B; better-than-expected margin, earnings and cash flow results reported for the quarter.
Bioprocessing momentum
Biotechnology segment core revenue +6% in Q4; bioprocessing grew high single digits driven by consumables (high single digits) and equipment (mid-single-digits); equipment orders increased sequentially for three quarters; company expects high single-digit core revenue growth in bioprocessing for full-year 2026 with equipment revenue improving to ~flat.
Diagnostics strength and Cepheid acceleration
Diagnostic core revenue +2% in Q4; Clinical Diagnostics mid-single digit growth (Leica and Radiometer ~+10% each, Beckman Coulter mid-single digits); Cepheid respiratory revenue ~ $500M in Q4 and company now models ~ $1.8B respiratory revenue for FY2026 under a normal season; Cepheid non-respiratory core tests grew low double-digits (sexual health ~+30%, HAI mid-teens).
Innovation driving commercial traction
Accelerated product introductions across the portfolio with ~25% YoY growth in new product revenue; notable launches include Cytiva bioreactor formats and resins, SCIEX Xenotop 8600 (up to 30x sensitivity), Beckman/Beckman Coulter and Cepheid FDA-cleared GI multiplex panel, contributing to customer impact and share gains.
Strong cash generation and financial flexibility
$5.3B FY free cash flow, strong conversion ratio and commentary that debt/EBITDA is below ~2 (analyst noted), leaving the company positioned to pursue disciplined M&A and capital deployment given improving valuations and ample balance sheet capacity.
Productivity actions delivering benefit
Approximately $250M of cost actions taken in 2025 with an estimated ~ $0.30 EPS benefit included in guidance; management expects these savings to be durable and to contribute to margin improvement over the year.
DHR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DHR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 28, 2026 | $235.75 | $224.54 | -4.76% |
Oct 21, 2025 | $208.10 | $220.46 | +5.94% |
Jul 22, 2025 | $187.48 | $189.31 | +0.98% |
Apr 22, 2025 | $184.08 | $191.16 | +3.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Danaher Corp. (DHR) report earnings?
Danaher Corp. (DHR) is schdueled to report earning on Apr 28, 2026, Before Open (Confirmed).
What is Danaher Corp. (DHR) earnings time?
Danaher Corp. (DHR) earnings time is at Apr 28, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DHR EPS forecast?
DHR EPS forecast for the fiscal quarter 2026 (Q1) is 1.94.
